ASHP Delegates Take a Measured Approach to DVO

Denver—ASHP waded into the complex issue of closed-system drug-transfer devices (CSTDs) and drug vial optimization (DVO) with a policy statement calling for the recognition of “a growing body of evidence” that supports the ability of CSTDs to maintain drug sterility beyond the six-hour limit set by the U.S. Pharmacopeial Convention General Chapter <797>.